Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA.
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Am Soc Clin Oncol Educ Book. 2021 Mar;41:358-375. doi: 10.1200/EDBK_320129.
The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.
近年来，复发多发性骨髓瘤的治疗领域已经大大扩展，因为许多具有新作用机制的药物已经问世，即使在晚期疾病中也增加了反应并延长了生存时间。大量新的治疗方案带来了平衡毒性和使治疗方案与骨髓瘤的生物学以及与患者治疗史和个人偏好相关的复发性质相匹配的挑战。在此，我们提供了早期和晚期复发疾病的治疗选择概述，并讨论了新兴的免疫治疗方法的作用。
